The high cost of insulin isn't from manufacturing but from the complex distribution chain of wholesalers, pharmacies, and insurers. Project Insulin's core strategy is to bypass this system entirely with a direct-to-patient mail-order pharmacy model, effectively eliminating the middlemen who inflate the final price.

To achieve an affordable price for its advanced cancer test, Delphi prioritizes algorithmic complexity over "wet lab" complexity. This strategy keeps physical sample processing simple and low-cost, putting the innovation into scalable software (AI/ML) to analyze the data, which is key for mass adoption.

Healthcare has historically been a service, with costs tied to licensed professionals. AI models like Gemini and ChatGPT are changing this by providing medical advice, effectively turning healthcare into a product. This shift, currently tolerated by regulators, could dramatically lower costs and increase access, just like software products.

Mark Cuban reveals the primary barrier to making generic drugs in the US isn't production cost, which can be cheaper than overseas, but the prohibitive FDA application fees costing hundreds of thousands per drug.

The high cost of bringing an AI model to market ($5-10M) limits adoption to elite hospitals. By reducing validation costs 100x (to $50-100k), innovators can lower prices, making AI accessible to all hospitals and creating a viable ROI.

Elon Musk uses this metric to identify manufacturing inefficiencies. A high ratio between the cost of a finished part and its raw materials—a high 'idiot index'—signals a significant opportunity for cost reduction through smarter, first-principles-based manufacturing techniques.

The ratio of patients to optometrists is worsening dramatically, projected to shift from 1:5000 today to 1:8000 in a decade. This widening provider gap, driven by a declining pipeline of new doctors, makes automated solutions like iBot's vision testing kiosk a necessity, not just a convenience.

The primary challenge for many MedTech innovations is not the initial science but translating a lab process into a robust, scalable, and GMP-compliant manufacturing system. This requires a shift from proving a concept to ensuring consistent quality and patient safety.

Drug development gets more expensive annually because its primary cost is manual lab work by highly-paid scientists. The rising cost of this labor (Baumol's cost disease) outpaces efficiency gains from new tools. Automation is the only way to reverse this trend.